RxDoctor Payments Data

Brett Lu, MD

Psychiatry · Honolulu, HINPI 1649331760

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,349, 4.0 times the $336 reported in 2019. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,635in general payments, 2019–2025

Across 87 payments — averaging $53.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$839
  • Alkermes, Inc.$706
  • Neurocrine Biosciences, Inc.$527
  • Teva Pharmaceuticals USA, Inc.$454
  • Johnson & Johnson$409
  • Acadia Pharmaceuticals Inc$397
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,618100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,635 in reported general payments places this provider in the 90th percentile of 183 psychiatry providers in Hawaii.

See all psychiatry providers in Hawaii

Medicare billing

Part B allowed, 2024
$55,292
Medicare patients
145
Services billed
425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$15,850
Aripiprazole76$5,248
Escitalopram Oxalate167$3,877
Risperidone41$2,703
Trazodone Hcl160$2,358
Citalopram HbrCitalopram Hydrobromide129$1,831
Quetiapine Fumarate54$1,296
Haloperidol16$1,217
Memantine Hcl26$971
Gabapentin31$942
Duloxetine Hcl23$905
Divalproex Sodium22$763
Olanzapine28$525
Mirtazapine36$479
Prazosin Hcl14$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$839$15,85011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 psychiatry providers in Hawaii.

Other psychiatry in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →